Download PDF

1. Company Snapshot

1.a. Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer.


The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Show Full description

1.b. Last Insights on GNLX

Genelux Corporation's recent performance was negatively impacted by the company's decision to raise $10.5 million through an underwritten offering of common stock in March 2025, which may have diluted shareholder value. Additionally, the company's fourth quarter and full year 2024 financial results, released in March 2025, showed a lack of significant progress in its clinical trials, with no notable updates on its Olvi-Vec treatment for Platinum Resistant/Refractory Ovarian Cancer. The recent upgrade to a Zacks Rank #2 (Buy) in June 2025 may have been a response to the company's efforts to align with the U.S. Food and Drug Administration on the approval pathway for Olvi-Vec, but this development may not have been enough to offset the company's recent challenges.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Nov -05

Source: globenewswire.com

Card image cap

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Aug -07

Source: globenewswire.com

Card image cap

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Jul -07

Source: globenewswire.com

Card image cap

Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know

Jun -02

Source: zacks.com

Card image cap

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

May -06

Source: globenewswire.com

Card image cap

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar -28

Source: globenewswire.com

Card image cap

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Mar -25

Source: globenewswire.com

Card image cap

Genelux Corporation Announces New Chief Financial Officer

Feb -03

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Diagnostic and Therapeutic Solutions

Expected Growth: 15.4%

Growing demand for targeted and personalized cancer therapies, increasing adoption of viral-based platforms, and rising investments in cancer research and development are expected to drive the growth of Genelux Corporation's diagnostic and therapeutic solutions.

7. Detailed Products

Oncolytic Viruses

Genelux Corporation's oncolytic viruses are genetically engineered to selectively target and destroy cancer cells while leaving healthy cells intact.

Viral Vector-based Vaccines

Genelux's viral vector-based vaccines utilize the company's proprietary oncolytic viruses to stimulate an immune response against cancer cells.

Gene Therapies

Genelux's gene therapies involve the use of oncolytic viruses to deliver therapeutic genes to cancer cells, promoting their destruction.

Immunotherapies

Genelux's immunotherapies harness the power of the immune system to fight cancer, using oncolytic viruses to stimulate an immune response.

Oncolytic Virus-based Diagnostics

Genelux's oncolytic virus-based diagnostics utilize the company's proprietary viruses to detect and monitor cancer.

8. Genelux Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Genelux Corporation's threat of substitutes is moderate due to the availability of alternative cancer treatments, but the company's unique oncolytic virus-based approach provides some protection.

Bargaining Power Of Customers

Genelux Corporation's customers, primarily hospitals and research institutions, have limited bargaining power due to the company's specialized products and services.

Bargaining Power Of Suppliers

Genelux Corporation's suppliers of raw materials and equipment have some bargaining power, but the company's diversified supply chain and long-term contracts mitigate this risk.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants with innovative technologies could potentially disrupt Genelux Corporation's market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Genelux Corporation faces intense rivalry from established companies and new entrants, which could impact its market share and pricing power.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 11.45%
Debt Cost 3.95%
Equity Weight 88.55%
Equity Cost -11.89%
WACC -10.07%
Leverage 12.94%

11. Quality Control: Genelux Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fennec Pharmaceuticals

A-Score: 6.0/10

Value: 8.2

Growth: 8.6

Quality: 6.4

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Synlogic

A-Score: 4.8/10

Value: 7.2

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Dyadic International

A-Score: 4.5/10

Value: 8.2

Growth: 5.0

Quality: 4.6

Yield: 0.0

Momentum: 8.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
GlycoMimetics

A-Score: 3.7/10

Value: 6.2

Growth: 4.6

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Mersana Therapeutics

A-Score: 3.4/10

Value: 9.2

Growth: 4.8

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Genelux

A-Score: 3.2/10

Value: 6.0

Growth: 4.2

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.64$

Current Price

4.64$

Potential

0.00%

Expected Cash-Flows